The lowering of the price target by Cantor Fitzgerald could potentially lead to a decrease in the stock price of ALX Oncology Holdings in the short term as it indicates a lower expected value of the company's stock. However, the maintained Overweight rating suggests that the analyst still believes the company's stock is expected to outperform.